Abstract
QScience.com is the innovative and collaborative, peer-reviewed, online publishing platform from Hamad bin Khalifa University Press (HBKU Press). It offers a fast and transparent Open Access scholarly publishing process, which is centered on the author, bringing their research to a global audience.
Highlights
The two adult types of bone marrow (BM) can be distinguished: the red marrow consisting of hematopoietic tissue, including Hematopoietic Stem Cells (HSCs) capable of producing around 500 billion blood cells per day; and the yellow marrow mainly made up of fat cells
In vitro studies demonstrated that Mesenchymal Stem Cells (MSCs) present attractive characteristics like immune-regulatory effects; capacity to stimulate neovascularization, endogenous stem cell proliferation and differentiation, capacity to modify the micro-environment, prevent scarification, fibrosis and aptitude to differentiate into various mesoderm derived tissue
Like TIME, SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI) trial was designed to examine the effect of timing of intracoronary injection of 10 mL of mononuclear BM derived cells at different interval, 3– 4 days or 5 – 7 weeks after successful primary Percutaneous Coronary Intervention (PCI).[23]
Summary
The two adult types of bone marrow (BM) can be distinguished: the red marrow consisting of hematopoietic tissue, including Hematopoietic Stem Cells (HSCs) capable of producing around 500 billion blood cells per day; and the yellow marrow mainly made up of fat cells. Very short time after the publication of the first experimental study of the use of Bone Marrow Cells (BMCs) for the treatment of post Myocardial Infarction (MI) heart failure (HF) in a small animal model,[14] clinical trials of this form of therapy started.[15] This was followed by an extremely large number of trials with mixed results,[16,17,18,19,20] and even the alarming establishment of commercial clinics in different countries. SWISS-AMI The four-month results of this trial were published in Circulation earlier this year.[22] Like TIME, SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI) trial was designed to examine the effect of timing of intracoronary injection of 10 mL of mononuclear BM derived cells at different interval, 3– 4 days or 5 – 7 weeks after successful primary PCI.[23] The authors randomized 200 patients to controls, early and late cell infusion.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
